43 results
8-K
EX-99.1
ACXP
Acurx Pharmaceuticals Inc
15 May 24
Acurx Pharmaceuticals, Inc. Reports First Quarter 2024 Results and Provides Business Update
7:13am
statements in this press release about our future expectations, plans and prospects, including statements regarding our strategy, future operations, prospects
FWP
ACXP
Acurx Pharmaceuticals Inc
2 Apr 24
Free writing prospectus
7:31am
Cure Data (94 days out) ▪ Jan ‘24 : Microbiome head - to - head comparison to standard of vancomycin Clinical, Regulatory WW Strategy ▪ Q2 ’24: FDA … Meeting – finalize Ph3 mandate ▪ 2H ‘24: Launch international strategy for commercialization in EU, UK, Japan & CDN ▪ File for FDA QIDP Designation
8-K
EX-99.1
t8h2yod
18 Mar 24
Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
4:15pm
8-K
EX-99.1
8pv91
14 Nov 23
Acurx Pharmaceuticals, Inc. Reports Third Quarter 2023 Results and Provides Business Update
4:05pm
8-K
om7ew8jc2k6j
3 Nov 23
Acurx Announces Positive Top-Line Ibezapolstat Phase 2 Efficacy Results with 96% Clinical Cure Rate in Patients with C. difficile Infection
4:05pm
8-K
EX-99.1
z04 038hlosrmpee5
3 Nov 23
Acurx Announces Positive Top-Line Ibezapolstat Phase 2 Efficacy Results with 96% Clinical Cure Rate in Patients with C. difficile Infection
4:05pm
8-K
jrjzlsim878zbwu
2 Oct 23
Other Events
4:41pm
8-K
EX-99.1
4015n9nsoswsq563f
2 Oct 23
Other Events
4:41pm
8-K
EX-99.1
74yr9yq6l751ql8lc24w
14 Aug 23
Acurx Pharmaceuticals, Inc. Reports Second Quarter 2023 Results and Provides Business Update
7:10am
424B3
46a58e
13 Jul 23
Prospectus supplement
4:32pm
8-K
EX-99.1
fepwklr36uol42wto
17 May 23
Acurx Pharmaceuticals, Inc. Announces Pricing of $4.0 Million Registered Direct Offering
4:19pm